Parallax Health Sciences (OTCMKTS:PRLX) versus Qiagen (NYSE:QGEN) Head-To-Head Comparison

Parallax Health Sciences (OTCMKTS:PRLX) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Insider and Institutional Ownership

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Parallax Health Sciences and Qiagen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parallax Health Sciences	0	0	0	0	0.00
Qiagen	1	8	4	1	2.36

Qiagen has a consensus target price of $42.43, indicating a potential upside of 1.72%. Given Qiagen’s stronger consensus rating and higher possible upside, analysts clearly believe Qiagen is more favorable than Parallax Health Sciences.

Profitability

This table compares Parallax Health Sciences and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Parallax Health Sciences	N/A	N/A	N/A
Qiagen	19.16%	14.40%	8.40%

Earnings and Valuation

This table compares Parallax Health Sciences and Qiagen”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parallax Health Sciences	N/A	N/A	N/A	N/A	N/A
Qiagen	$2.10 billion	4.09	$424.88 million	$1.91	21.84

Qiagen has higher revenue and earnings than Parallax Health Sciences.

Summary

Qiagen beats Parallax Health Sciences on 10 of the 10 factors compared between the two stocks.

About Parallax Health Sciences

Parallax Health Sciences, Inc. is an integrated digital healthcare company. It is engaged in the provision of personalized patient care through remote healthcare services, behavioral health systems, and Point-of-Care diagnostic testing. The firm operates through the following segments: Remote Patient Monitoring, Behavioral Health Systems, and Corporate. The Remote Patient Monitoring segment offers a technology platform that includes a complete remote patient care delivery system through PHM. The Behavioral Health Systems segment includes the intellectual property, Reliable Evidence-Based Outcomes Optimization Technologies, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc. The Corporate segment consists of management and administrative services. The company was founded on July 6, 2005 and is headquartered in Los Angeles, CA.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.